engasertib

News

A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.

News

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.